Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL

NCT02757248 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Boehringer Ingelheim is discontinuing their volasertib development program

Conditions

PTCL
CTCL

Interventions

DRUG: Volasertib
DRUG: Romidepsin

Sponsor

Anne Beaven, MD

Collaborators

[object Object]
[object Object]